Tilray Brands is an Execution and Growth Story to be Aware of!

During the last month, Tilray Brands, Inc. (Nasdaq: TLRY) (TSX: TLRY) has reported a series of developments and we are closely monitoring the leading global cannabis-lifestyle and consumer packaged goods (CPG) business.

Although Tilray Brands reported several important milestone since July, the stock has been trading in a volatile range and we are closely monitoring price movements from here. From formulating a plan to capture additional market share in Canada and abroad to acquiring strategic assets, the Canadian Licensed Producer (LP) is executing on a global growth strategy and we want our readers to be aware of the most recent developments.

Today, we have highlighted 6 of the most recent announcements by Tilray Brands and are favorable on the direction the management team is bringing the business. Over the next few years, we expect these announcements by the leading global cannabis firm to have a considerable impact on its domestic and international cannabis operations.

1. September 6^th – Tilray initiated a policy roundtable with German regulators on recreational cannabis legalization. In the meeting, the German Drug Commissioner presented the plan for recreational cannabis legalization and repeated its intent to release a first draft of the bill in the coming months.
2. September 1^st – Tilray Brands expanded Good Supply’s award-winning cannabis portfolio to include high-potency concentrates, hash bats, and Orange Frost live resin. The brand is a leading cannabis brands for flower, pre-rolls, vapes, concentrates, in Canada.
3. September 1^st – As part of an agreement to take over $39 million of debt from joint venture partner, the leading global cannabis CPG issued more than 10 million shares. Tilray plans to use the net proceeds for general corporate purposes (i.e., research and development, sales and marketing activities, acquisitions or investments, and capital expenditures).
4. August 25^th – Tilray Brands released new medical cannabis products and launched a program which is designed to support patients. We are favorable on the focus on Canada and will monitor how the program is able to scale across the country
5. August 23^rd –Tilray Brands received approval and verification from The Natural Health Science Foundation (NHSF) to use its flagship product in clinical trials in Australia and in New Zealand. We are favorable on this focus and the potential value that can be generated by positive clinical trial results.
6. August 17^th – Tilray Brands received approval to commercialize branded medical cannabis products in Poland which further expands its product offering and distribution across pharmacies in Europe.

We classify Tilray as a global cannabis leader due to it having operations in Canada, in the United States (US), in the European Union (EU), in Australia, and in Latin America. We are favorable on the diversity of the markets the cannabis company is levered to. Going forward, we will monitor the growth of Tilray on the international side of the business and believe the market underappreciates the amount of value it can generate.

Due to the continued execution, we believe Tilray is a pioneer in cannabis research, cultivation and distribution. Currently, the company offers a diverse portfolio of products (cannabis products, hemp-based foods, and alcoholic beverages) in more than 20 countries and we are bullish on this aspect of the story.

If you are interested in learning more about Tilray Brands, please send an email to support@technical420.com with the subject “Tilray Brands is a Global Cannabis Leader” to be added to our distribution list.

Share

Tags

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Technical420.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Top Stories